Alkermes Plc

ALKS remains in Stage 2 advancing within an intact long-term uptrend with a medium-term bullish bias. Price is currently consolidating into the rising 9/21 EMA zone on lighter volume, with no exhaustion or rejection signals visible. Short-term timing is neutral, so we defer execution and await a clean acceptance at the EMAs or a shallow pullback back into dynamic support before committing to a buy.

• ↑Q1 2026 net sales $338.1M (+38% YoY) driven by proprietary products
• ↑Interim alixorexon narcolepsy trial shows sustained wakefulness improvements
• ↓Overvalued ~64% above GF Value; negative earnings yield and low profitability